表紙
市場調查報告書

Biomedtracker:全球製藥和醫療設備行業的分析和展望(2020年第四季度)

Biomedtracker Q4 2020 Outlook Report

出版商 Datamonitor Healthcare 商品編碼 967497
出版日期 內容資訊 英文 77 Pages
商品交期: 最快1-2個工作天內
價格
Biomedtracker:全球製藥和醫療設備行業的分析和展望(2020年第四季度) Biomedtracker Q4 2020 Outlook Report
出版日期: 2020年10月09日內容資訊: 英文 77 Pages
簡介

本報告分析了全球製藥和醫療器械行業的最新情況(2020年第4季度),並分析了最近一個季度該行業的主要趨勢(總計35例,治療藥物和醫療器械的發展,資本)。交易概要),按階段(按階段),按藥物類別,按疾病組,主要資本交易/業務發展(業務聯盟/合作,企業合併/收購(併購),藥品認證等)的詳細趨勢我們將為您提供諸如概述和規模,總體批准可用性(LOA)以及與以前的分析結果進行比較之類的信息。

目錄

  • 目錄
  • 概述
    • 關於作者
    • 免責聲明
  • 先前分析摘要(2020年第三季度):對市場的影響
  • 毒品
    • SPN-812(SUPN),用於注意力缺陷多動障礙(ADHD)
    • BIVV009(SNY)用於自身免疫性溶血性貧血(AIHA)
    • Margetuximab治療乳腺癌(MGNX)
    • VGX-3100(INO)用於宮頸發育不良
    • Omecamtiv Mecarbil(口服藥物)用於充血性心力衰竭(CHF)和心肌病(AMGN)
    • Actemra(RHHBY)用於新的冠狀病毒感染(COVID-19)
    • COVID-19的AZD1222(AZN)
    • 適用於COVID-19的BNT162(BNTX)
    • COVID-19的mRNA-1273(MRNA)
    • 布羅西醇(PXS)用於囊性纖維化(CF)
    • PTI-NC-733(PTI)用於囊性纖維化(CF)
    • SAR341402(SNY)用於I型糖尿病
    • 瀰漫性大細胞B型細胞淋巴瘤(DLBCL)--NHL(非霍奇金淋巴瘤)--Brayanji(BMY)
    • EYSUVIS(KALA)用於乾眼症(眼科)
    • RGN-259(RGRX),用於乾眼症(眼科)
    • REGN-EB3(REGN)用於伊波拉熱
    • CPP-1X/Slindak(MNK)用於家族性結腸腺瘤病(FAP)
    • VT-1161(Mycovia)用於非系統性真菌感染
    • Hokkinson-Gilford-Progeria綜合徵的Zokinvy(EIGR)
    • 尿嘧啶(ALNY)用於高尿酸尿酸症
    • 嚴重抑鬱症(MDD)的SAGE-217(SAGE)
    • SGX942(SNGX)用於粘膜
    • Danielza(YMAB)用於神經內分泌腫瘤(NET)
    • Lorontis用於中性粒細胞減少/白細胞減少症(SPPI)
    • Tanezumab(PFE)用於骨關節炎和骨關節炎
    • Viveglon(UROV),用於膀胱過度活動症(OAB)
    • ERY-ASP(ERYP)用於胰腺癌
    • Terra Grenastat(CALA)用於腎細胞癌(RCC)
    • 精神分裂症的ALKS3831(ALKS)
  • 設備
    • BuMA可降解藥物洗脫支架系統用於冠狀動脈疾病(Sino Medical)
    • 對於非小細胞肺癌(NSCLC))Optune(NVCR)
    • 橢圓形肥胖的胃氣球(變態)
  • 資本交易趨勢
    • 愛奧尼斯(Ionis)收購Akcea
    • Mylan收購了Aspen的歐洲血栓形成業務
    • 生命與蛋白質穩定的合併
  • 最有影響力的活動(2020年第四季度)
目錄
Product Code: #BMT

Summary

In this report, we cover catalysts from 35 drugs, devices, diagnostics, and deals expected to occur in Q4 2020. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. These data points were provided using a combination of Pharmapremia, Informa's drug development benchmarking product utilizing Biomedtracker's LOA data to assist in informed decisions about drug pipeline prioritization, partnerships, and acquisitions, and drug approval data from Biomedtracker.

TABLE OF CONTENTS

Contents

Summary

About the Author

Disclaimer

Outcomes of Biomedtracker's Large Impact Drug Catalysts from the Q3 2020 Outlook Report

Drugs

SPN-812 for Attention Deficit Hyperactivity Disorder (ADHD) (SUPN)

BIVV009 for Autoimmune Hemolytic Anemia (AIHA) (SNY)

Margetuximab for Breast Cancer (MGNX)

VGX-3100 for Cervical Dysplasia (INO)

Omecamtiv Mecarbil (Oral) for Congestive Heart Failure (CHF) and Cardiomyopathies (AMGN)

Actemra for COVID-19 (RHHBY)

AZD1222 for COVID-19 (AZN)

BNT162 for COVID-19 (BNTX)

mRNA-1273 for COVID-19 (MRNA)

Bronchitol for Cystic Fibrosis (CF) (PXS)

PTI-NC-733 for Cystic Fibrosis (CF) (PTI)

SAR341402 for Diabetes Mellitus, Type I (SNY)

Breyanzi for Diffuse Large B-Cell Lymphoma (DLBCL) - NHL (BMY)

EYSUVIS for Dry Eye (Ophthalmology) (KALA)

RGN-259 for Dry Eye (Ophthalmology) (RGRX)

REGN-EB3 for Ebola (REGN)

CPP-1X/Sulindac for Familial Adenomatous Polyposis (FAP) (MNK)

VT-1161 for Fungal Infections - Non-Systemic (Mycovia)

Zokinvy for Hutchinson-Gilford Progeria Syndrome (EIGR)

Lumasiran for Hyperoxaluria (ALNY)

SAGE-217 for Major Depressive Disorder (MDD) (SAGE)

SGX942 for Mucositis (SNGX)

Danyelza for Neuroendocrine Tumors (NET) (YMAB)

September 2020 / 5

Rolontis for Neutropenia / Leukopenia (SPPI)

Tanezumab for Osteoarthritis and Osteoarthritis Pain (PFE)

Vibegron for Overactive Bladder (OAB) (UROV)

ERY-ASP for Pancreatic Cancer (ERYP)

Telaglenastat for Renal Cell Cancer (RCC) (CALA)

ALKS 3831 for Schizophrenia (ALKS)

Devices

BuMA Biodegradeable Drug Coating Coronary Stent System for Coronary Artery Disease (Sino

Medical)

Optune for Non-Small Cell Lung Cancer (NSCLC) (NVCR)

Elipse Gastric Balloon for Obesity (Allurion)

Deals

Acquisition of Akcea by Ionis

Acquisition of Aspen's European Thrombosis Business by Mylan

Merger of Yumanity and Proteostasis

Q4 2020 Large Impact Catalysts……………………………….……………………………………………………………………………48